Unknown

Dataset Information

0

Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group.

ABSTRACT: Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a rare subtype associated with FLT3-internal tandem duplication (ITD) and poor outcomes. The clinical outcomes of paediatric patients with t(6;9) with and without FLT3-ITD treated on six consecutive cooperative trails were evaluated. In contrast to patients without t(6;9), those with t(6;9) had a significantly lower complete remission rate, higher relapse rate (RR), and poor overall survival (OS). Within t(6;9) patients, those with and without FLT3-ITD had an OS of 40% and 27% respectively (P > 0·9), demonstrating that t(6;9) is a high-risk cytogenetic feature in paediatric AML and its clinical impact is independent of the presence of FLT3-ITD.

SUBMITTER: Tarlock K 

PROVIDER: S-EPMC4079767 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group.

Tarlock Katherine K   Alonzo Todd A TA   Moraleda Pilar Palomo PP   Gerbing Robert B RB   Raimondi Susana C SC   Hirsch Betsy A BA   Ravindranath Yaddanapudi Y   Lange Beverly B   Woods William G WG   Gamis Alan S AS   Meshinchi Soheil S  

British journal of haematology 20140325 2

Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a rare subtype associated with FLT3-internal tandem duplication (ITD) and poor outcomes. The clinical outcomes of paediatric patients with t(6;9) with and without FLT3-ITD treated on six consecutive cooperative trails were evaluated. In contrast to patients without t(6;9), those with t(6;9) had a significantly lower complete remission rate, higher relapse rate (RR), and poor overall survival (OS). Within t(6;9) patients, those with and withou  ...[more]

Similar Datasets

Unknown Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34).
| S-EPMC8404557 | biostudies-literature
Unknown Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML.
| S-EPMC5045383 | biostudies-literature
Unknown Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
| S-EPMC5519068 | biostudies-other
Unknown getITD for FLT3-ITD-based MRD monitoring in AML.
| S-EPMC8075860 | biostudies-literature
Unknown Structural and numerical variation of FLT3/ITD in pediatric AML.
| S-EPMC2384125 | biostudies-literature
Unknown Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
| S-EPMC3501718 | biostudies-literature
Unknown Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia.
| S-EPMC5882915 | biostudies-literature
Unknown CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.
| S-EPMC7138400 | biostudies-literature
Unknown FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML.
| S-EPMC8651734 | biostudies-literature
Unknown Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
| S-EPMC4834220 | biostudies-literature